

Pharma Equity Group



A Pharma Company with Lower Risk but Equivalent Upside Potential

Pharma Equity Group (“PEG” or “the Company”), through the Company’s subsidiary, *Reponex*, employs a drug repositioning strategy, which involves finding new uses for active substances used in previous recognized treatments, thus allowing the Company to circumvent phase I trials. PEG has a pipeline of six candidates in Phase II, targeting therapeutic areas such as Peritonitis, Chronic Wounds, IBD, and Colorectal Cancer, where there is currently no adequate treatment. The business strategy involves out-licensing the programs after Phase II to a pharma company capable of bringing the drugs to the market. PEG’s strategy enables a capital-light and highly scalable business model, offering a shorter route to market with equivalent upside potential, yet mitigating the typical risks associated with the pharmaceutical industry. Based on an rNPV-model, a potential present value per share of DKK 1.4 is derived in a Base scenario.

▪ Extensive Markets with Unmet Medical Needs

PEG targets vast markets with an estimated prevalence of approx. 12m patients in the Company’s key markets. These markets are forecasted to witness steady growth, fueled by factors such as an elderly population, rising preference for local treatments, and increased R&D investments. PEG’s solutions have great potential to capture significant market shares if they reach commercialization.

▪ Broad and Diversified Pipeline

PEG’s extensive pipeline comprises six candidates across four indication areas, potentially advancing through Phase II toward licensing agreements. The current treatment solutions for the Company’s targeted indications predominantly involve systemic treatments, whereas PEG is repositioning its compounds to local administration. Backed by a robust IP portfolio many candidates utilize the leading active substance, GM-CSF. This strategic utilization of the same compound across multiple candidates enables PEG to capitalize on collective results, leading to cost savings and a more streamlined path to market.

▪ Repositioning and Out-Licensing Model

The repositioning approach allows PEG to “reuse” established data and documentation concerning the drugs. As a result, it bypasses Phase I and significantly reduces the development risks. Additionally, PEG’s out-licensing model, which aims to transition directly from Phase II and there after to licensing agreements, enables a low-cost base by out-sourcing most business functions such as production and marketing, consequently reducing operational and execution risks.

▪ Valuation

The valuation, determined through a risk-adjusted net present value model (rNPV), uses estimated royalties as the foundation. By risk-adjusting for a 22% likelihood of approval and applying a discount rate of 13.1%, a potential market value of DKK 1,421m is derived, corresponding to DKK 1.4 per share.


VALUATION RANGE

Bear DKK 0.5 **Base** DKK 1.4 **Bull** DKK 2.3

KEY INFORMATION

| | |
|----------------------------|-----------------------------|
| Share Price (2024-02-26) | 0.34 |
| Shares Outstanding | 1,022,963,883 |
| Market Cap (DKKm) | 351.9 |
| Net cash(-)/debt(+) (DKKm) | 20.8 |
| Enterprise Value (DKKm) | 372.7 |
| List | Nasdaq Small Cap Copenhagen |
| Quarterly report 4 2023 | 2024-03-20 |

SHARE PRICE DEVELOPMENT



TOP SHAREHOLDERS (SOURCE: THE COMPANY)

| | |
|----------------------------------|-----|
| Biopharma Holding ApS | N/A |
| Beier Holding ApS | N/A |
| Niels Erik Jespersen Holding ApS | N/A |

| Estimates (DKKm) | 2025E | 2026E | 2027E | 2028E |
|----------------------|-------------|-------------|--------------|--------------|
| Risk-adj. Royalties | 36,7 | 87,0 | 221,5 | 391,8 |
| COGS | -2,0 | -2,0 | -2,0 | -2,0 |
| Gross profit | 34,7 | 85,0 | 219,5 | 389,8 |
| R&D | -15,0 | -20,0 | -17,5 | -15,0 |
| Administrative costs | -12,0 | -13,0 | -14,0 | -14,0 |
| EBIT | 7,7 | 52,0 | 188,0 | 360,8 |
| Net Income | 3,7 | 39,0 | 145,9 | 281,4 |
| P/S | 9,6 | 4,0 | 1,6 | 0,9 |
| EV/S | 10,2 | 4,3 | 1,7 | 1,0 |
| P/E | 96,2 | 9,0 | 2,4 | 1,3 |
| EV/EBIT | 48,5 | 7,2 | 2,0 | 1,0 |

Table of Contents

| | |
|---------------------|-------|
| Investment Thesis | 3 |
| Company Description | 4-6 |
| Market Analysis | 7-8 |
| Financial Forecast | 9-13 |
| Valuation | 14-17 |
| Bull & Bear | 18 |
| Management & Board | 19-20 |
| Appendix | 21-25 |
| Disclaimer | 26 |

ABOUT THE COMPANY

Pharma Equity Group A/S (“PEG” or “the Company”), listed on the Nasdaq Copenhagen Stock Exchange, places a strong emphasis on its subsidiary, Reponex Pharmaceuticals A/S (“Reponex”). Through the Company’s repositioning strategy, Reponex finds new uses for active substances that are being used in other treatments. Currently, Reponex has a pipeline of six product candidates in phase II, targeting therapeutic areas such as Peritonitis, Chronic Wounds, IBD (Crohn’s Disease and Pouchitis), and Colorectal Cancer. PEG’s strategy is to out-license the clinical programs after the phase II trial to a pharmaceutical company capable of bringing the drugs to market.


CEO AND CHAIRMAN

| | |
|----------|---------------------------|
| CEO | Thomas Kaas Selsø |
| Chairman | Christian Vinding Thomsen |

ANALYST


| | |
|--------|-----------------------------|
| Namn | Oscar Mårdh |
| Phone | +46 760 44 29 70 |
| E-mail | oscar.mardh@analystgroup.se |

Value Drivers




One of the main value drivers is assessed to be the clinical development milestones associated with the current pipeline candidates. Additionally, converting the initial discussions with potential licensing partners into commercial licensing agreements constitutes a substantial value driver going forward. Moreover, positive progress in redeeming the receivable from Portinho S.A. is assessed to be an additional value driver during 2024.

Historical Profitability




PEG’s candidates are currently in Phase II and are not generating any revenue. Given that further development requires significant investments in R&D, both PEG and the Company’s subsidiary, Reponex, have faced high investments and thus losses in the last few years. Considering PEG is expected to start generating revenue in 2025, profitability is still not in close sight. The rating is based on PEG’s historical profitability and does not reflect future estimates.

Management & Board



The management and board possess substantial expertise in regard to pharmaceuticals, research, business development, and other relevant areas vital for PEG’s success in clinical development and executing the Company’s out-licensing strategy. Insiders collectively own approximately 5% of the Company, incentivizing them to deliver shareholder value. However, for a higher grade, Analyst Group prefers to see increased insider ownership.

Risk Profile



At the end of Q3-23, PEG’s cash balance amounted to approx. DKK 1.5m. Alongside a bridge loan of DKK 6.5m, the convertible loans of DKK 16.0m and an estimated monthly burn rate of DKK -1.6m, the possibility that PEG needs to pursue some form of external capital raise to strengthen the financial position cannot be ruled out. Additionally, the uncertainty regarding the receivable from Portinho S.A. is contributing to the higher risk profile.



VAST MARKETS WITH UNMET MEDICAL NEED

PEG addresses extensive markets, where Analyst Group estimates the prevalence in the Company's key markets, namely the EU, US and Japan, to encompass approximately 12 million patients who are suffering from the targeted diseases. The markets are forecasted to witness steady growth during the coming years, driven by factors such as rising prevalence, an aging population, heightened preference for local treatments, and increased R&D investments to develop adequate treatment options. PEG's local treatment solutions have great potential to capture significant market shares in these expanding markets if they reach commercialization. To shed light on one of the indication areas PEG is addressing, colorectal cancer stands as the second most prevalent cancer and the second leading cause of cancer-related deaths. This underscores the significant demand for an effective treatment capable of preventing and treating tumors.

Promising Pipeline of Phase II Candidates

6 CANDIDATES IN PHASE II

PEG currently has a broad and diversified pipeline consisting of six promising candidates within four indication areas, all of which are in Phase II and are currently on their way to licensing agreements. PEG focuses on therapeutic areas characterized by unmet medical needs, where the Company aim to introduce innovative solutions to well-established domains where existing treatment options are inadequate. The Company targets Peritonitis, Chronic Wounds, IBD (Crohn's Disease and Pouchitis), and Colorectal Cancer, and the current treatment solutions for the aforementioned indications largely involve systemic treatments, whereas PEG is repositioning its compounds for local treatment solutions. The Company holds a strong IP-portfolio with several patents for promising local applications, with many of the candidates using the leading active substance, GM-CSF. This provides an advantage, as the Company can leverage the results obtained from the compound in other candidates, leading to cost savings and a shorter route to market.

Capital Light via Scalable Repositioning and Out-Licensing Model

PEG employs a pharmaceutical approach known as repositioning, which involves exploring new uses or indications for existing drugs already approved for treating other diseases. This allows PEG to use drugs with established safety profiles, leveraging the well-known data and documentation and enabling the Company to "reuse" this information, consequently skipping Phase I trials. By going straight to Phase II, PEG maintains the same upside potential without the conventional development risks inherent in the pharmaceutical industry. Moreover, PEG operates through an out-licensing model, aiming to transition directly from Phase II to licensing agreements with established pharmaceutical companies. This strategic approach enables PEG to maintain a low-cost base by outsourcing the majority of business functions such as production, sales and marketing, thereby minimizing the operational and all execution risks commonly faced by smaller biotech companies, and thus reap the benefits of recurring royalty streams. In essence, PEG's repositioning and out-licensing strategy enables a capital-light and highly scalable business model, providing a shorter route to market with reduced risk, while simultaneously presenting the potential for substantial royalties.

LOWER RISK SAME UPSIDE POTENTIAL

Valuation: A Summary

DKK 1.4 PER SHARE (BASE SCENARIO)

The valuation of PEG is derived using a risk-adjusted net present value model (rNPV). Analyst Group estimates that PEG will secure licensing agreements, where the estimated royalties, based on projected sales, constitute the foundation of the valuation model. The total royalties are then risk-adjusted with a 22% likelihood of approval, reflecting that PEG's candidates are currently in Phase II. Applying a discount rate of 13.1%, a potential market value of DKK 1,421m is derived, corresponding to DKK 1.4 per share.

Risks Embedded in PEG's Business Model

DEVELOPMENT-, FINANCING-, AND LICENSING RISK

While PEG's repositioning model involves less risk compared to traditional pharmaceutical companies, there are still some apparent risks embedded in the business model. First and foremost, the Company faces the risk of development not going according to plan, or, in the worst case, clinical trial failure, which puts pressure on the financial position, as PEG currently does not generate any revenue and is dependent on alternative financing solutions. Additionally, PEG is dependent on finding suitable licensing partners, and given that the Company has not yet established a track record from previous commercial licensing, the challenge of securing partners going forward is notable.

Established in 2002 under the name Gudme Raaschou Vision A/S, Pharma Equity Group initially operated as an investment company solely focused on securities. In 2009, the Company underwent a name change to Blue Vision A/S, signifying a strategic shift towards Danish investment and development properties. This was followed by a redefined focus in 2014 toward international and innovative real estate projects.

In April 2022, PEG initiated a conditional takeover offer to the shareholders of Reponex Pharmaceuticals A/S ("Reponex"), which gained regulatory approval in February 2023. A few weeks prior to the approval, the Company once again underwent a name change, this time to the current name: Pharma Equity Group A/S. Following the transaction, a new and well-experienced management and board joined the Company. The newly issued shares commenced trading on the 28th of March 2023, and as of today, Reponex essentially constitutes all of PEG's asset base. Reponex is a clinical-stage biopharmaceutical company focused on developing novel treatments for various diseases, including bacterial peritonitis, chronic wounds, inflammatory bowel diseases (IBD), and colorectal cancer. The Company currently has six programs in phase II, each distinguished by unique features. PEG's primary focus lies in supporting and nurturing the growth and development of Reponex by leveraging the Company's know-how and broad network of industry partners.

Business Model – Repositioning

PEG's business model differentiates itself from traditional pharmaceutical companies by employing a drug repositioning strategy. This strategy involves repositioning established APIs (active pharmaceutical ingredients) in terms of new indications, novel administration methods, and combinations with other APIs. Essentially, it entails discovering new uses or indications for existing drugs already approved for treating other diseases. The advantage lies in the fact that the fundamental toxicity and side effects of the drug are already known and documented, allowing for the "reuse" of this documentation. Consequently, PEG can reduce development time, bypassing phase I trials, and bringing the pipeline programs directly to a clinical phase II stage to gather pertinent clinical data demonstrating the efficacy of the drug candidates, which cuts the development time by at least three years and in the best case up to eight years¹. PEG's repositioning strategy provides the same upside potential but without the traditionally associated risks inherent in the pharmaceutical industry, resulting in a shorter time to market and lower costs.

One of the most famous examples of drug repositioning is Viagra, initially developed to treat chest pain. The drug became a success and generated peak annual sales exceeding USD 2 billion. Although this outcome was unforeseen, it exemplifies the power of repositioning existing drugs for new indications.

PEG's Business Model Shortens Development Time and Offers Lower Risk with Equivalent Upside Potential.

Illustration of PEG's Repositioning and Out-License Model



Source: Analyst Group (illustration)

Reponex mainly focuses on the repositioning and reformulation of the following APIs:

- **Molgramostim** ("GM-CSF") - small protein (cytokine) that stimulates the production of white blood cells, crucial for immune response.
- **Fosfomycin** - a non-toxic broad-spectrum antibiotic.
- **Metronidazole** - antibiotic against toxic anaerobic bacteria.
- **Sucralfate** – small molecule binding to ulcers to create a protective layer against acid.
- **Hyaluronan** – glucose-based molecule promoting wound healing.

It's worth noting that GM-CSF is frequently utilized across several of PEG's candidates, enabling cost synergies as the Company can leverage results obtained from these compounds in other candidates.



**3-8 YEARS
SHORTER
DEVELOPMENT
TIME**

STRONG PATENT PORTFOLIO

Intellectual Property (IP) Strategy

Repositioning existing drugs gives the possibilities of obtaining patent protection, even if the original patents on the active pharmaceutical ingredient are still in force. Potential patentable claims include exploring new indications supported by proof-of-concept examples, developing new dosage regimens tailored for novel indications, implementing new administration methods customized to the specific needs of the new indications, and creating different formulations aligned with any new administration method to maximize efficacy and acceptability. PEG aims for a flexible patent application, covering current and potential future uses of their treatments. The Company focuses on anticipated applications and clinical trial objectives, exploring new patent applications for unforeseen trial benefits, with the aim of securing patent protection in key markets, namely the US, the EU, and Japan. See page 25 for a patent overview.

LOW-COST BASE AND A SCALABLE BUSINESS MODEL

Out-Licensing Strategy

PEG aims to out-license the Company's programs after broadened phase II trials to pharmaceutical companies with established sales and marketing departments. This ensures the capacity to successfully introduce new drugs into the pharmaceutical market, allowing PEG to leverage the strengths of commercial partners for later stages of drug development and market entry. Upon achieving a commercial out-license agreement, PEG will not manage the business functions such as production, storage, sales and marketing, as these will be handled either by the licensing partner or outsourced to external parties. PEG's out-license strategy enables the Company to maintain a low-cost base and the flexibility to scale up or down rapidly with respect to relevant human knowledge resources, a key factor and driver of success. An out-licensing agreement aligned with market standards is estimated to yield revenue streams for PEG in the form of upfront- and milestone- payments, as well as tiered royalties. In return for full or partial funding of the phase III clinical trials and regulatory approval, the licensee is expected to receive the marketing authorization (MA) for the medicinal product, either globally or for specific territories.

The Company is currently engaged in initial dialogues with potential partners and ideally seeks a partner interested in entering license agreements for several of the Company's candidates. This would secure increased revenue streams for PEG, while the partner could leverage the fact that PEG's repositioning strategy is, to a large extent, based on the same active substances, thereby facilitating a smoother process.

CLINICAL PARTNERS



Reponex's Clinical Strategy

Reponex's clinical strategy involves collaborations with globally renowned institutions and hospitals, alongside engaging top experts in specific clinical areas. Through this approach, Reponex executes its clinical development in close interaction with the latest knowledge through key opinion leaders and research, which often leads to publications directly or indirectly validating the merit of its programs. Reponex has collaborated with Herlev University Hospital (RXN-011) and is presently collaborating with both Bispebjerg Hospital (RXN-021) and Zealand University Hospital (RXN-041, RXN-051).

Pipeline Candidates

RNX-011 - Bacterial Peritonitis

Individuals suffering from perforated appendicitis or other bowel perforations may experience bacterial peritonitis, characterized by a bacterial infection affecting the abdominal lining. If left untreated, peritonitis can lead to lasting harm to internal organs, prolonged hospitalization, and, in severe cases, fatality.

Current treatment options include intravenous antibiotics, exposing the body to systemic levels of the drug, in contrast to RNX-011, which is applied directly into the peritoneal cavity at surgery, resulting in the highest concentration of the drug at the site of infection. The Company has completed a clinical study with RNX-011 administered directly into the abdominal cavity, which indicated that this solution is more effective for treating peritonitis than the standard approach. In the phase II efficacy study, RNX-011 demonstrated promising results, allowing for the discharge of all six patients within 2 to 21 hours (median 13 hours) on follow-up oral antibiotics, compared to 67-169 hours (median 84 hours) for patients treated with intravenous antibiotics before they could leave the hospital.¹

RNX-011's primary aim is to enhance the treatment of peritonitis, resulting in reduced hospitalization times, improved patient outcomes, and cost savings for healthcare services. PEG currently holds a patent in the US, the EU and Japan for RNX-011, and expects to start generating revenue streams in the year of 2025.



¹<https://pubmed.ncbi.nlm.nih.gov/32432123/>

RNX-021, 022 and 023 - Chronic Wounds

Chronic leg ulcers are commonly linked to conditions such as diabetes, venous insufficiency, local pressure, or ischemia (insufficient blood flow). A common factor among these conditions is the insufficient local blood supply, which hinders the delivery of necessary substances to sustain the full activity of cells involved in the healing process. The white blood cells and macrophages fail to perform their functions effectively, with macrophages not providing their usual stimulation for the healing processes.

CURRENT TREATMENTS



RNX-021-023

Non-healing wounds and ulcers comprise various categories, each requiring specialized treatment such as debridement, infection control, and local wound care. PEG has developed several candidates (RNX-021-23) targeting diverse approaches to address these conditions. The Company has formulated two gels for topical application (RNX-021-022) to expedite the healing of chronic skin wounds and ulcers. Additionally, RNX-023, available in powder form, combines an active substance with an antibiotic for application on severely infected chronic wounds. PEG's treatment solutions aim to accelerate the healing process by restoring the functionality of the body's own immune defense cells and eliminating bacteria.

The Company is currently conducting a clinical proof-of-concept study with RNX-021 for non-healing venous leg ulcers. PEG has obtained a patent for RNX-023 in the EU and Russia¹ and has submitted patent applications for the other two candidates. Income generation from RNX-021-022 is expected by 2026, while revenue from RNX-023 is estimated from 2027 and onwards.

RNX-041 - IBD (Crohn's Disease, Ulcerative Colitis and Pouchitis)

Inflammatory Bowel Disease (IBD), including Crohn's disease, Ulcerative Colitis and Pouchitis, involves chronic inflammation in the digestive tract due to an abnormal immune response. Symptoms include abdominal pain, diarrhea, fatigue, fever, and occasional bleeding. IBD patients may also face co-morbidities like respiratory issues, colon cancer, depression, anxiety, heart problems, arthritis, and dental deterioration.

The current treatment involves systemic medication, and approximately 50% of Crohn's patients require surgery. RNX-041 provides intra-intestinal treatment, a localized approach that decreases systemic inflammatory effects and reduces the burden of intestinal bacteria. PEG's treatment has the potential to reduce the need for surgery, resulting in significant cost savings for the healthcare system.

Pouchitis is a condition that develops in patients with Ulcerative Colitis when medical treatment is no longer effective in relieving symptoms or to treat complications of the disease. In such cases, many patients undergo a surgical procedure where the entire colon is removed. Pouchitis symptoms include painful and frequent toilet visits with bloody diarrhoea, which significantly impacts quality of life. PEG's treatment solution for pouchitis holds the potential to attain *orphan drug status*, typically designated for treatments addressing rare diseases or disorders. Orphan drug status includes advantages such as protocol assistance, access to the centralized authorization procedure, and ten years of market exclusivity. The benefits of an orphan drug designation is further explained on page 8.

RNX-041 is currently undergoing clinical trials at Zealand University Hospital, and the data from the study is expected to be presented during 2024. Currently, RNX-041 holds a patent in the US, and has submitted a patent application within the EU. The Company expects to start generating revenue from RNX-041 in the year of 2025.

RNX-051 - Colorectal Cancer and Colon Adenomas

Recent discoveries indicate that specific bacteria in the large intestine, such as fusobacteria, toxin-producing enterococci, coliforms, and bacteroides spp., play a role in promoting the generation, growth, and spread of colorectal cancer tumors. These bacteria may form biofilms that invade the colon's surface mucous layer and can infect tumors, fostering growth and resistance to radio- and chemotherapy.

Reponex has developed a pharmaceutical composition featuring RNX-051 for an innovative method to eradicate or reduce these cancer-promoting bacteria and eliminate bacterial biofilm through intraintestinal administration. An exploratory clinical Phase II trial for RNX-051 is currently underway at Zealand University Hospital. The Company has submitted a patent application covering a substantial portion of the potential market, including the EU, the US, Japan, and Russia¹. Revenue is expected from 2025 and onwards.

¹Reponex has no activities in Russia and will not seek any business operations in Russia while the sanctions imposed by EU apply.

POTENTIAL
SURGERY
REDUCTION

ORPHAN DRUG
CANDIDATE

2025
EXPECTED
REVENUE
GENERATION

1% OF URGENT



HOSPITAL ADMISSIONS

Peritonitis

Secondary peritonitis poses an increasing challenge and burden for individuals as well as the healthcare system, constituting 1% of urgent hospital admissions and ranking as the second most common cause of sepsis (blood poisoning).¹ Furthermore, the overall mortality rate for secondary peritonitis is 6%, increasing to 35% in patients who develop severe sepsis.¹ Secondary peritonitis has an impact on individuals of all ages, irrespective of their health status. Given that this condition affects a significant number of patients worldwide, often necessitating extended stays in the Intensive Care Unit (ICU), the economic consequences are vast.²

The global peritonitis treatment market is expected to grow at a CAGR of 6.1% from 2020 to 2028.³ The current treatment solution involves intravenous antibiotics, leading to patients often being hospitalized for days, highlighting the substantial need for effective treatments that can reduce hospital stays and, consequently, overall health costs. The estimated market growth is attributed to a rising prevalence and increased investments in R&D to develop permanent and adequate treatment options, originating from both public and government sectors.


Chronic Wounds

6.8% CAGR
2022-2030E

According to Fortune Business Insight, the global chronic wound care market was valued to USD 12.5bn in 2022 and is expected to grow at a CAGR of 6.8%, reaching USD 21bn by 2030.⁴ The increasing prevalence of diverse chronic wounds worldwide creates a significant need for treatment products, leading to increased adoption of wound dressings, devices, and other related products. Moreover, the growing elderly population is anticipated to drive market growth, given that the senior demographic often experiences slower healing capabilities. Approximately 1-2% of the population in developed countries is estimated to experience a chronic wound at some point in their lives, and the increasing aging population is expected to contribute to these figures, as wound closure tends to be inversely correlated with age.⁵

The Global Chronic Wound Market is Expected to Grow With a CAGR of 6.8%.

Chronic Wound Care Market Size, 2022-2030E



Source: Fortune Business Insights (2023)

IBD (Crohn's Disease, Ulcerative Colitis & Pouchitis)

USD 25.7bn
ESTIMATED
MARKET VALUE
2027E

The global inflammatory bowel disease (IBD) market had, according to ReportLinker, an estimated value of USD 21.3bn in 2023 and is expected to experience a 4.8% CAGR during 2023-2027, thereby reaching USD 25.7bn by 2027.⁶ The increasing incidences of Crohn's disease and ulcerative colitis are anticipated to drive the demand for treatments related to IBD, as these treatments are commonly utilized to alleviate bowel inflammation, minimizing and preventing medical complications. The overarching growth driver of the IBD market is a heightened preference for effective yet less invasive symptomatic therapeutics and biologics. This preference, coupled with the increasing popularity of biosimilars (biological medicine highly similar to an already approved biological medicine), is expected to significantly influence the future landscape of the market. Additionally, advancements in understanding the disease process and improvements in endoscopic techniques, equipment, and devices are anticipated to pave the way for interventional IBD treatments.

¹<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889898/?report=printable>

²<https://journals.sagepub.com/doi/10.1177/1457496920984078>

³<https://www.databridgemarketresearch.com/reports/global-peritonitis-treatment-market>

⁴<https://www.fortunebusinessinsights.com/industry-reports/chronic-wound-care-market-100222>

⁵<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017042/>

⁶https://www.reportlinker.com/p06317616/Inflammatory-Bowel-Disease-Treatment-Global-Market-Report.html?utm_source=GNW

Market Analysis

IBD POSES AN ECONOMIC BURDEN ON SOCIETY

According to DelveInsight, the market size of Crohn's disease in the seven major markets, namely, US, France, Germany, Italy, Spain, UK, and Japan had an estimated value of USD 7.8bn in 2021 and is expected to witness a 3.0% CAGR during 2021-2032, leading to a market size of USD 11.8bn by 2032.¹ In Europe, 10-30% of patients suffering from Crohn's, and 5-10% of ulcerative colitis patients require a surgery within 5 years², indicating the severe economic burden associated with IBD.

The Pouchitis market is relatively small compared to the overall IBD market. According to IMARC, the pouchitis market was estimated to be valued at USD 52m in 2023 and is expected to observe a 7.7% CAGR during 2024-2034, reaching USD 118m by the end of the forecast period.³


Pouchitis is a rare disease, as indicated by the aforementioned market size. Therefore, PEG's pouchitis treatment has the potential to attain orphan drug status. Orphan drugs are pharmaceuticals designed to address rare diseases or disorders that affect a limited number of individuals. Due to the pharmaceutical industry's limited interest in developing and marketing medications for conditions affecting a small patient population under typical market circumstances, the European Medicines Agency (EMA) provides various incentives to promote the development of such medicines.⁴ For instance, orphan drugs receive protocol assistance, where the European Medicines Agency offers sponsors guidance on study requirements to demonstrate quality, benefits, and risks, and this assistance is available at a reduced charge. Furthermore, all designated orphan medicines undergo a centralized assessment for marketing authorization in the European Union, enabling companies to submit a single application for regulatory approval, leading to a quicker and smoother process. Another incentive is that orphan drugs can be granted ten years of market exclusivity.

Colorectal Cancer

The colorectal cancer market was valued at USD 19bn in 2022 and is estimated to witness a 4.0% CAGR from 2022 to 2030, reaching USD 26bn by 2030.⁵ In the year 2020, approximately 12.7% of new cancer diagnoses and 12.4% of cancer-related deaths were attributed to colorectal cancer in EU-27 countries. This positioning marks it as the second most prevalent cancer, following breast cancer, and the second leading cause of cancer-related mortality, after lung cancer.⁶

The anticipated growth of the global colorectal cancer market is attributed to the elevated prevalence and mortality rates of colorectal cancer, which are driving heightened interest in discovering effective treatment solutions for the prevention and treatment of tumors. Additionally, the expanding pharmaceutical industry in emerging markets within developing countries is expected to further contribute to market growth in the upcoming years.

Colorectal Cancer Market



¹<https://www.delveinsight.com/report-store/crohns-disease-cd-market>

²<https://academic.oup.com/ecco-jcc/article/15/9/1573/6134782?login=false>

³<https://www.imarcgroup.com/pouchitis-market>

⁴<https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/orphan-designation-research-and-development/orphan-incentives>

⁵<https://www.databridgemarketresearch.com/reports/global-colorectal-cancer-treatment-market>

⁶https://ecis.jrc.ec.europa.eu/pdf/factsheets/Colorectal_cancer_en-Mar_2021.pdf


Revenue Forecast

The estimated revenue forecast for PEG is based on a top-down approach, where the estimated prevalence, peak market share, price per treatment, as well as royalty rate constitute the main parameters for forecasting the revenue for each indication. The model focuses on PEG's core markets, namely Europe, the US, and Japan, where the company currently holds granted patents or is estimated to receive them. The prevalence is expected to align with the forecasted market growth, as detailed on pages 7-8. Subsequently, a growth rate of 2% is applied to the remaining forecast period to encompass general GDP growth. It's worth noting that the forecast does not include the potential revenue related to the treatment of ulcerative colitis and colon adenomas, which represent additional options.

In a Base scenario, the sales cycle is calculated based on the commencement of revenue streams for each indication and the patent expirations of the Company's different candidates. This aligns with the industry's dynamics, where patent expirations markedly affect the capacity to generate significant revenues.

Revenue Forecast - RNX-011

RNX-011




To determine the prevalence of patients suffering from peritonitis, the number of peritonitis cases per 1000 hospital admissions has been used and then converted to align with PEG's target markets. Peritonitis affects 9.3 patients per 1000 hospital admissions¹, and with approximately 34m hospital admissions in the US during 2022², the estimated annual prevalence in the US amounts to 0.32m cases. Applying the same prevalence rate to Europe and Japan, the addressable market amounts to 1.04m patients suffering from peritonitis. RNX-011 is estimated to attain a peak market share of 7%. The candidate is expected to commence revenue generation in 2025, followed by a ramp up phase in the first four years and a maturation phase spanning from 2029 to 2039. Subsequently, a sharp decline is anticipated as the patent expires in the year of 2040.

The average hospital admission costs per day in the US are approximately USD 2.9k (EUR 2.7k). In PEG's Phase IIb for RNX-011, it was demonstrated that patients were discharged within 2-21 hours, compared to 67-169 hours using the standard treatment, representing a difference of approximately six days at the higher end of the ranges. When assessing the price for RNX-011, the average hospital cost per day has been adjusted for the higher range (21/24) during which patients were discharged using RNX-011. This adjustment yields approximately EUR 2.3k per treatment, whereas Analyst Group is estimating a treatment price of EUR 2k per treatment. Considering this, the projected price appears significantly lower than the potential reduction in healthcare spending compared to the longer hospital stays using the current treatment option.


Revenue Forecast - RNX-021-23

RNX-021-23



According to DelveInsight, the estimated total diagnosed prevalent cases of chronic wounds in the 7MM (US, Germany, France, Italy, Spain, UK and Japan) were approx. 7m in 2021.³ By applying the forecasted market growth of 6.8%, an estimated prevalence of 8.5m patients suffering from chronic wounds are used as the base in 2024. Given the diverse nature of the market, encompassing various categories of wounds each with its specific treatment, the estimated peak market share is set at 2.8%. The variability in wound types and their unique treatment requirements contributes to a more fragmented market, making it challenging for any single solution to capture a larger share. Analyst Group estimates that RNX-021-23 will begin generating revenue in 2026, and with the patent expiring in 2035, the sales cycle is projected to be shorter, with the maturity phase spanning from 2030 to 2034. The projected price is determined by the health service's benefit from reducing the mean time required for wound care, with a mean cost/week of standard care at EUR 1.1k.

RNX-041



Revenue Forecast - RNX-041

The revenue forecast for RNX-041 is based on estimated sales targeting Crohn's disease and pouchitis. As previously mentioned, potential sales from treating ulcerative colitis are not included in the current model, and hence, this can be viewed as an option, presenting additional potential upside to the revenue forecast. The model has factored in the patent expiration in 2035 for both Crohn's disease and pouchitis.

¹<https://bmjopen.bmj.com/content/10/1/e034326>

²<https://www.aha.org/statistics/fast-facts-us-hospitals>

³<https://www.delveinsight.com/report-store/chronic-wounds-epidemiology-forecast>

In 2021, the total prevalent cases of Crohn's disease in the 7MM were approx. 1.6m, according to DelveInsight's estimates¹. With the patent set to expire in 2035, we anticipate a relatively short sales cycle at maturity. A ramp-up stage is expected between 2025 and 2028, followed by a six-year period of maturity leading up to the patent expiration phase. RNX-041 addressing Crohn's disease is estimated to reach a peak market share of 7.6%. The estimated direct health care costs associated with Crohn's disease amount to EUR 3.5k per patient annually², providing the basis for our target price in the model.

As previously mentioned, PEG's treatment for pouchitis serves as a potential orphan drug candidate, which implies that it's a rare disease that affects a limited number of individuals and thus defines the addressable market. Approximately 0.3% of the population in the US and Europe are diagnosed with ulcerative colitis.³ Among these patients, about 20-30% eventually undergo proctocolectomy, with the majority opting for ileal pouch-anal anastomosis (IPAA).⁴ Analyst Group estimates that 25% of patients undergo IPAA. Additionally, pouchitis is the most common complication of IPAA⁴, with Analyst Group estimating its prevalence to be 32.5%. Taking these factors into account, Analyst Group estimates that approximately 0.23m patients suffer from pouchitis in the US and Europe. Analyst Group estimates a peak market share of 7.6% and an average treatment price of EUR 3.5k, aligning with that of Crohn's disease.

While the EMA offers ten years of market exclusivity for medicines granted orphan designation, it's important to note that PEG's pouchitis treatment, as of today, is only considered a potential candidate for orphan drug status. Consequently, market exclusivity has not been factored into the current model, and similar to the ulcerative colitis treatment, should be viewed as an additional option.

RNX-051



Revenue Forecast - RNX-051

The American Cancer Society projects that, by 2024, the number of colorectal cancer cases in the US will reach 0.11m.⁵ In 2020, the European Commission estimated new cases in the EU-27 countries to be 0.34m⁶, and World Cancer Research Fund International reported an estimated prevalence of 0.15m in Japan during the same year.⁷ These figures, adjusted for the forecasted market growth in colorectal cancer between 2020 and 2024, serve as the basis for Analyst Group's prevalence estimate, resulting in 0.66m patients in 2024.

Given that colorectal cancer is the second most prevalent cancer and the second leading cause of cancer-related mortality, the demand for an effective and localized treatment solution is critical. Analyst Group estimate that this demand would soon be reflected in the market share of RNX-051, given successful commercialization, which is the foundation to our estimated peak market share of 15%.

Public Health England estimates the total cost for treating stage 1 colon cancer to GBP 3.6k (EUR 4.2k).⁸ However, Analyst Group is adopting a conservative approach by estimating a target price of EUR 3k, with the aim of enhancing the margin of safety in the model and accommodate potential variations in price levels across different markets.

Summary Revenue Forecast

The table below presents an overview of the estimated sales cycles for the various candidates, based on the patent lifetimes.

| Candidate | Indication | Year | | | | | | | | | | | | | | | | | | | |
|------------|-------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--|--|
| | | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | | |
| RNX-011 | Peritonitis | | | | | | | | | | | | | | | | | | | | |
| RNX-021-23 | Chronic Wounds | | | | | | | | | | | | | | | | | | | | |
| RNX-041 | Crohn's | | | | | | | | | | | | | | | | | | | | |
| | Pouchitis | | | | | | | | | | | | | | | | | | | | |
| RNX-051 | Colorectal cancer | | | | | | | | | | | | | | | | | | | | |

¹<https://www.delveinsight.com/report-store/crohns-disease-cd-market>

²<https://academic.oup.com/ecco-jcc/article/15/9/1573/6134782?login=false>

³[https://www.valueinhealthjournal.com/article/S1098-3015\(18\)30856-8/fulltext](https://www.valueinhealthjournal.com/article/S1098-3015(18)30856-8/fulltext)

⁴<https://pubs.rsna.org/doi/abs/10.1148/rq.2018170113?journalCode=radiographics>

⁵<https://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html>

⁶https://ecis.jrc.ec.europa.eu/pdf/factsheets/Colorectal_cancer_en-Mar_2021.pdf

⁷<https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics/>


⁸<https://assets.publishing.service.gov.uk/media/5a821a44ed915d74e6235cc1/cost-effectiveness-early-diagnosis-colorectal-cancer.pdf>



| Summary of Inputs - Revenue Forecast | | | | | | | |
|--------------------------------------|-------------------|-------------------------------------|---------------------------|---------------------------|---------------------------|----------------|--------------|
| Candidate | Indication | Prevalence 2024 (Million People) | Prevalence Growth CAGR | Continuous Growth Rate | Estimated Market share | Price (EUR) | Royalty Rate |
| RNX-011 | Peritonitis | 1.04 | 6.1% | 2.0% | 7.0% | 2000 | 22.5% |
| RNX-021-23 | Chronic Wounds | 8.53 | 6.8% | 2.0% | 2.8% | 1075 | 22.5% |
| RNX-041 | Crohn's | 1.75 | 3.0% | 2.0% | 7.6% | 3500 | 22.5% |
| | Pouchitis | 0.23 | 7.7% | 2.0% | 7.6% | 3500 | 22.5% |
| RNX-051 | Colorectal cancer | 0.66 | 4.0% | 2.0% | 15.0% | 3000 | 22.5% |

Estimated Royalties From the Various Candidates During the Forecast Period Before Risk-Adjustments.

Estimated Pre Risk-Adjusted Royalties, Base Scenario, 2025-2042E¹



Source: Analyst Group (estimates)

¹License agreements and royalties are expected to be received toward the end of 2025.

Royalty Rate


The financial model concentrates exclusively on royalties as the source of income. Despite Analyst Group's assessment that PEG might likely receive upfront and milestone payments upon entering potential licensing agreements, the challenge lies in estimating the timing and magnitude of these payments, justifying the exclusive focus on potential royalties. Nevertheless, Analyst Group has elevated the estimated royalty rate to accommodate potential upfront and milestone payments that would otherwise not be included in the forecast.

The graph below shows a benchmark of royalties reported in licensing contracts for small molecules¹. As the figure shows, the range of royalties reported for Phase II candidates lies between 5%-40% of net sales with an average and median royalty rate of 20%. Hence, Analyst Group argues that a royalty rate of 22.5% is reasonable and comparable to industry standards, especially considering that the model excludes potential upfront and milestone payments.

22.5%
ESTIMATED
ROYALTY RATE

Benchmark of Royalties Reported in Licensing Contracts for Small Molecules.

Each Bar Represents an Individual Product Royalty for a Phase II Candidate, 2004 onwards



Source: Borshell & Dawkes, 2009; Analyst Group (illustration)

¹<https://link.springer.com/article/10.1057/jcb.2009.13>



Capital Expenditures (Capex)

Reponex has a history of virtually nonexistent capex. Analyst Group estimates that the majority of investments will be directed towards human resources to accelerate candidate development and conduct more comprehensive studies as the Company progresses through the development stages. Consequently, these investments are estimated to be directly accounted for in the P&L statement.

Due to PEG's business model, focused on out-licensing and out-sourcing as much as possible, potential partners are assessed to possess the extensive production facilities necessary to advance the candidates through phase III, which is the primary reason why PEG is not expected to require any significant investments in the coming years. Hence, the model assumes no capex investments going forward.

Net working capital (NWC)

PEG operates a capital-light business model, outsourcing functions like production, sales, and marketing. Without its own production or manufacturing facilities, PEG avoids tying up capital in inventory and accounts payable. Although fluctuations in accounts receivable linked to royalties are expected upon reaching commercialization, the anticipated offsetting effect in the long run suggests a net impact of zero. Consequently, no significant changes in net working capital are estimated, and they are accordingly not accounted for in the model.

Cost Structure

Analyst Group estimates that PEG, upon reaching maturity, will attain a gross margin approaching 100%, given that the Company's out-licensing partners will bear the majority of the COGS, as PEG won't have any in-house production or manufacturing. The financial model incorporates a nominal portion of COGS to cover expenses associated with intellectual property (IP), compliance, and related considerations.

Considering that PEG's candidates are currently in different stages of clinical phase II and given the characteristics of the business and industry, R&D costs will continue to constitute a significant portion of the overall cost base for the foreseeable future as the Company progresses with its clinical trials. These R&D costs comprise both internal and external expenses related to development studies, including personnel expenditures and material costs. Until 2021, R&D expenses were capitalized as intangible assets, which are subject to periodic impairment testing. However, from 2021, R&D costs are expensed as incurred over the income statement. Additionally, administrative costs, which include expenses related to administrative staff, traveling, the executive board, and office premises and supplies, are expected to remain a significant component of the overall cost base in the future.

Analyst Group estimates that as the Company advances toward phase III and potential licensing agreements, R&D and administrative costs will increase. This escalation will be driven by the necessity for roles such as Contract Research Organizations (CROs), additional personnel in Chemistry, Manufacturing, and Controls (CMC), as well as regulatory experts, resulting in increased personnel costs in the coming years. However, this rise is not expected to be proportionate to the estimated drastic increase in revenue from securing commercial licensing agreements. With PEG's strategy to outsource functions such as production, storage, sales, and marketing, the Company can maintain a low-cost base, which will pave the way for the embedded operational leverage in the scalable business model. Moreover, it's worth highlighting again that PEG do not intend to engage in expensive phase III trials, as the Company instead aims to find the right licensing partner that will bear full or partial part of the costs associated with the phase III clinical trials, as well as covering regulatory costs.

PEG'S STRATEGY
ENABLES A
CAPITAL-LIGHT
BUSINESS MODEL



OUT-SOURCING
CREATES A
LOW-COST BASE



Receivable from Portinho S.A.

PEG has a receivable from Portinho S.A. ("Portinho") on the balance sheet dating back many years. As of the last September 2023, the receivable is valued at a fair value of DKK 64m, representing approximately 18% of the current market cap (DKK 352m).

The history traces back to 2014 when Blue Vision, PEG's former name, acquired shares in Portinho. A few years later, PEG sought to divest its approximately 79% ownership in Portinho and in 2019, PEG successfully sold Portinho for a total of EUR 11m, with the agreement encompassing all of PEG's shares and receivables from Portinho. In 2021, an agreement was reached to accept payment of the outstanding amount by July 1, 2023, at the latest, but this was later expedited due to Portinho's financial constraints. Currently, the receivable accrues interest at a rate of 2% per quarter, and the Company is actively working to convert the receivable into cash on the balance sheet. The uncertainty surrounding the potential redemption of the receivable increases over time, and market sentiment suggests skepticism regarding PEG's ability to receive the cash.

Analyst Group has not factored in the receivable when valuing PEG, considering the historical pattern of non-redemption and the prevailing uncertainty. However, it's worth noting that this presents an additional option in our forecast, as the cash could be of significant importance to sustain the Company financially until securing potential licensing agreements.

Financial Position


Given the nature of PEG's business model, the Company is currently not generating any revenue, and thus, there are no internally generated free cash flows available to support the continuous development of the Company's candidates. Consequently, PEG consistently needs to seek alternative financing solutions to maintain operations until potential licensing agreements are secured, allowing the Company to become cash flow positive.

At the end of Q3-23, PEG's cash balance amounted to approx. DKK 1.5m. In Q1-24, the Company issued convertible loans which were fully subscribed, enabling PEG to loan a total of DKK 16.0m. PEG aims to increase the level of convertible loans up to DKK 20m during 2024. Given that PEG's is expected to start generating revenue in 2025, the loans are vital.

With the latest reported cash position (DKK 1.5m), the bridge loan of DKK 6.5m obtained after the Q3 report, coupled with the convertible loans of totally DKK 16.0m and an estimated monthly burn rate of DKK -1.6m, Analyst Group estimates that PEG's financial position is sufficient to finance the Company until the end of Q4-24, all else being equal. However, there is a risk that the burn rate will increase as the Company progresses with development, and hence, Analyst Group cannot rule out the possibility that PEG may need to pursue some form of external capital raise to further strengthen its financial position. It's worth mentioning that we do not factor in that PEG will receive the receivable from Portinho, in that case, the liquidity position would not be a concern in the coming year.

The Current Liquidity Position is Estimated to Sustain the Company Until Q4-24.

Estimated Liquidity Development, 2023-2024E



Source: Analyst Group (estimates)

¹As of 2024-02-07, DKK 15.5m out of DKK 16.0m has been paid out to PEG.

**DKK 64m
RECEIVABLE
SERVES AS AN
OPTION**

**ESTIMATED TO BE
FINANCED UNTIL
Q4-24**

Risk-Adjusted Net Present Value (rNPV)

The valuation of PEG is determined through a risk-adjusted net present value (rNPV) model. In this model, future royalties are probability-adjusted and then discounted to their present value using an appropriate discount rate (WACC).

Before PEG can bring its various candidates to the market, it must successfully navigate through several clinical phases and approvals. As a result, there is considerable uncertainty about when and if the treatments will obtain clinical approval, leading to the generation of substantial income streams. To manage this high level of uncertainty, the estimated royalties are risk-adjusted. The *Probability of Success* (PoS) for each development phase is drawn from a study by Paul et al. (2010): 34% for passing phase II, 70% for phase III, and 91% for regulatory approval. All of PEG's candidates are currently in phase II, leading to a cumulative PoS, also known as *Likelihood of Approval* (LoA), of approximately 22%. Moreover, if the Company successfully manages to complete the different phases, the LoA gradually increases, and in that case, it will be taken into consideration at a later stage when the potential progression has been proven.

22%
CUMULATIVE
PROBABILITY
OF SUCCESS


| | Preclinical | Phase I | Phase II | Phase III | Approval |
|-----|-------------|---------|----------|-----------|----------|
| PoS | 69% | 54% | 34% | 70% | 91% |
| LoA | 8% | 12% | 22% | 64% | 91% |

Risk-Adjusted Free Cash Flows

As previously mentioned, a LoA of 22% is used to risk-adjust the total estimated royalties from the drug candidates. Based on the risk-adjusted royalties and deduction of forecasted costs, primarily R&D and administrative expenses, NOPAT is derived. Subsequently, certain assumptions are applied to determine the estimated free cash flows for the forecast period, with capex and changes in NWC constituting critical factors. However, for PEG, whose business model primarily relies on out-licensing candidates following phase II trials to pharmaceutical companies with substantial financial resources, capex is projected to be negligible. This is because the licensor takes responsibility for potential investments in facilities. Changes in NWC are expected to balance out over the long term, especially since PEG won't own their production or manufacturing facilities, thereby avoiding tying up capital in inventory and accounts payable. Hence, the NWC will consist of fluctuations in receivables, which in the long run suggests a net impact of zero.

Estimated Risk-Adjusted Free Cash Flows until the year of 2042.¹

Risk-Adjusted Free Cash Flows 2025-2042E



Source: Analyst Group (estimates)

¹The negative risk-adj. FCF in 2042E is attributed to the cost base surpassing the gross profit from royalties due to patent expiration.


Net Present Value of Risk-Adjusted Future Cash Flows

To calculate the present value of the risk-adjusted cash flows, a WACC of 13.1% is applied, which includes a discount attributed to PEG's size. By discounting the value of all future estimated risk-adjusted cash flows, a risk-adjusted present value can be derived. The chart below illustrates the net present value of the free cash flows for each individual year, and when aggregating these values and taking the current capital structure into account, a potential market value of DKK 1,421m is derived, corresponding to DKK 1.4 per share.

DKK 1.4
PER SHARE
(BASE SCENARIO)

Estimated Net Present Value of Risk-Adjusted Free Cash Flows until the year of 2042.

Net Present Value of Risk-Adjusted Free Cash Flows 2025-2042E



Source: Analyst Group (estimates)

Sensitivity Analysis

To address the sensitivity of our valuation to changes in the different factors incorporated into the rNPV-model, a sensitivity analysis is conducted. Given that PEG is estimated to generate the majority of the Company's free cash flows a few years ahead, the WACC has a notable impact on the valuation. Additionally, the estimated level of the Company's royalty rate has a significant impact on the future potential net present value of PEG, especially since the model does not account for potential upfront or milestone payments. Moreover, considering the complexity of the explicit model and the sensitivity of the future market value to specific factors, there exists a margin for error. Hence, the valuation should be regarded as an indication of the future potential that PEG's current candidates have, rather than as an absolute certainty. Below is an illustration of the impact of minor adjustments in WACC and royalty rate on PEG's share price in a Base scenario.

| | | Royalty Rate | | | | |
|------|-------|--------------|-------|-------|-------|-------|
| | | 20.0% | 21.3% | 22.5% | 23.8% | 25.0% |
| WACC | 11.1% | 1.40 | 1.50 | 1.60 | 1.70 | 1.80 |
| | 12.1% | 1.30 | 1.39 | 1.48 | 1.58 | 1.67 |
| | 13.1% | 1.21 | 1.29 | 1.39 | 1.47 | 1.55 |
| | 14.1% | 1.13 | 1.21 | 1.28 | 1.36 | 1.44 |
| | 15.1% | 1.05 | 1.12 | 1.20 | 1.27 | 1.35 |

Comparison With Listed Peers

Due to PEG's repositioning strategy and the specific target markets the Company is addressing, finding comparable peers in similar development phases proves to be challenging. Nevertheless, Analyst Group has identified a few peers with at least one drug candidate targeting one of PEG's indicated markets. Additionally, a comparison will be drawn with other companies in the industry currently having at least one phase II candidate, shedding further light on the valuation discrepancy. Analyst Group acknowledges that the peers mentioned below differ from PEG in many factors. However, the comparison should be considered as an additional indication of whether the Company's current market value is reasonable or not.

| Indication Peers | | Number of Candidates in Each Phase | | | | | | | |
|---------------------------|-------------|------------------------------------|------------|-------------|------------|------------|------------|------------|------------|
| Company ¹ | Mcap (DKKm) | Indication ² | Discovery | Preclinical | Phase I | Phase II | Phase III | Approval | Total |
| Tiziana Life Sciences Ltd | 349 | IBD (Crohn's) | 0 | 4 | 1 | 1 | 0 | 0 | 6 |
| MediWound Ltd. | 697 | Chronic wounds | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Alaunos Therapeutics Inc | 247 | Colorectal cancer | 1 | 1 | 6 | 0 | 0 | 0 | 8 |
| Average | 431 | | 0.3 | 1.7 | 2.7 | 0.7 | 0.0 | 0.3 | 5.7 |
| Median | 349 | | 0.0 | 1.0 | 1.0 | 1.0 | 0.0 | 0.0 | 6.0 |
| PEG | 352 | | 0 | 0 | 0 | 6 | 0 | 0 | 6 |

¹Data for peers taken from Nasdaq as of 2024-02-26, and exchange rate to DKK as of 2024-02-26²See next page for details on which phase the indication refers to



Tiziana Life Sciences Ltd. (“Tiziana”) is a biotech company currently developing several treatments in the following stages: preclinical, phase I and phase II. Among these, Tiziana has a drug designed to address Crohn’s disease. The approach involves orally administering the drug to the small and large intestine using an enteric-coated capsule formulation. Tiziana intends to conduct a Phase Ib study in the near term regarding the candidate targeting Crohn’s disease.



MediWound Ltd. (“MediWound”) focuses on non-surgical tissue repair, with one of its candidates specifically designed for the debridement of chronic and hard-to-heal wounds. This candidate is currently in Phase II, but MediWound intends to initiate Phase III studies in H2-24. Apart from the chronic wound treatment, MediWound has one candidate currently entering the commercialization phase and another drug in Phase I/II.



Alaunos Therapeutics Inc. (“Alaunos”) is committed to treating solid tumors through adoptive TCR-T cell therapy. One of the candidates targets colorectal cancer and is currently in Phase I. Additionally, Alaunos has five other candidates entering Phase I and two more candidates in the discovery/preclinical stages.

One can conclude that the average (median) company is valued at DKK 431m (DKK 349m). Among the comparable companies, MediWound stands out as it is valued the highest, featuring candidates entering commercialization and Phase III, albeit with only three candidates compared to PEG’s six. While Tiziana and Alaunos also have extensive candidate pipelines like PEG, they are all at earlier stages in the development process. In summary, PEG trades at a discount compared to MediWound that has progressed further in the development process but has only half the number of candidates. The other two comparable companies, with a similar candidate count, are in earlier development stages, showing relatively similar valuations to PEG.

To assess the relative valuation further, a selection has been made from a group of companies with at least one candidate in Phase II and none beyond this stage. Analyst Group is fully cognizant of the differing indication areas compared to PEG, recognizing that it significantly can influence the potential that should be considered in the valuation. Nevertheless, it underscores the notion that the notable valuation gap between PEG and other companies in the industry, possessing similar forward potential, is noteworthy. The average and median comparison company have a similar number of pipeline candidates as PEG but are more inclined towards early-stage development, whereas all of PEG’s candidates currently are in Phase II.

PEG has progressed considerably compared to the comparable companies, and all else being equal, the likelihood of PEG reaching the commercial phase for the Company’s candidates is currently significantly higher. For instance, a company with the majority of its candidates in the preclinical phase has a LoA of approx. 8% for the drug to reach commercialization and, consequently, generate revenues (see table on page 14). Comparing this with a phase II company, the LoA increases to 22%, naturally having a substantial impact on the future potential free cash flows upon which the valuations are built, as the LoA serves as the risk-adjusting percentage in this context. Additionally, it’s crucial to bear in mind that the earlier a company is in the development process, the more distant the estimated cash flows. This, when combined with a discount rate and the element of time, contributes to an additional negative impact on the overall valuation. Despite the abovementioned, PEG is currently valued at a fraction compared to the median company. Analyst Group assesses that the significant discrepancy in valuation is too wide, and that the present potential of PEG’s candidates is not fully incorporated into today’s valuation.

| Phase II Peers | | | Number of Candidates in Each Phase | | | | | | |
|--------------------------------|--------------|------------------------------|------------------------------------|-------------|------------|------------|------------|------------|------------|
| Company ¹ | Mcap (DKKm) | Indication ² | Discovery | Preclinical | Phase I | Phase II | Phase III | Approval | Total |
| Silence Therapeutics Plc | 6,061 | Cardiovascular Disease | 3 | 2 | 1 | 1 | 0 | 0 | 7 |
| Viking Therapeutics Inc | 26,564 | NASH & Obesity | 0 | 0 | 2 | 2 | 0 | 0 | 4 |
| Gritstone Oncology Inc | 1,605 | Metastatic colorectal cancer | 0 | 2 | 1 | 3 | 0 | 0 | 6 |
| Black Diamond Therapeutics Inc | 1,731 | NSCLC | 0 | 2 | 2 | 1 | 0 | 0 | 5 |
| Average | 8,990 | | 0.8 | 1.5 | 1.5 | 1.8 | 0.0 | 0.0 | 5.5 |
| Median | 3,896 | | 0.0 | 2.0 | 1.5 | 1.5 | 0.0 | 0.0 | 5.5 |
| PEG | 352 | | 0 | 0 | 0 | 6 | 0 | 0 | 6 |

¹Data for peers taken from Nasdaq as of 2024-02-26, and exchange rate to DKK as of 2024-02-26

²The indication mentioned in this table is the one where the company has made the most progress, in this case Phase II for all companies.


USD 405m
MEDIAN UPFRONT
FOR PHASE II 2023

Trends in the Life Science Industry

Based on an industry report from J.P. Morgan, the life science sector continues to attract significant attention from big pharma.¹ The number of deals, as well as upfront cash and equity payments, remains robust despite prevailing macroeconomic challenges. The sector saw a surge in dealmaking in 2021, accompanied by substantial inflows of capital, and although the current activity has declined from its peak, the ongoing transactions indicate that there is still much unfolding in the market. Big pharma has shown an increasing tendency to provide higher upfront payments as companies progress further in the development process. The median upfront payment of USD 405m in phase II companies during 2023 highlights big pharma's willingness to make substantial upfront investments, despite the inherent high risk involved.

Big Pharma Demonstrates Readiness for Significant Upfront Payments Despite High Associated Risks.

In-Licensing by Big Pharma: Median Upfront Cash & Equity by Stage at Signing, 2022 vs. 2023



Source: DealForma.com database, Analyst Group (illustration)

Precedent Transactions in the Market



USD 400m UPFRONT
&
USD 730m MILESTONES

In January 2023, Takeda Pharmaceutical Company Limited made an offer to HUTCHMED for the exclusive worldwide license to develop and commercialize the drug **Fruquintinib** in all territories outside of mainland China, Hong Kong, and Macau. Fruquintinib is a drug designed to block specific proteins that aid in tumor growth, offering a potential new treatment to colorectal cancer. The drug is approved in China and is currently awaiting global approval. HUTCHMED will receive USD 400m upfront, with up to USD 730m in milestone payments, as well as tiered royalties connected to net sales.

Another recent acquisition that is relevant to PEG is Grander Acquisition LLC's purchase of all the assets of RegenETP, Inc. (formerly known as PolarityTE, Inc.) during Q3-23. The acquired assets include PolarityTE's product in development, **SkinTE**, a treatment for patients suffering from chronic cutaneous ulcers, with a purchase price of USD 6.5m. SkinTE can be applied to various types of chronic wounds, and the product has recently entered the clinical phase for the majority of its intended applications.

The aforementioned deals demonstrate the substantial interest in disruptive treatments within PEG's indication areas. Despite PEG's colorectal cancer treatment, RNX-051, being in phase II and facing a longer journey to commercialization, the abovementioned licensing agreement indicates a noteworthy interest from major pharmaceutical companies and their readiness to invest significantly in the right candidate. Additionally, it's worth noting that PEG currently has three different candidates in regard to the chronic wound indication, all of which are in Phase II, in contrast to the acquisition of SkinTE, which represents one candidate at an earlier development stage.

Summary Valuation

To summarize, Analyst Group assesses that the potential within PEG's six current Phase II candidates is only partially reflected in today's valuation. The current valuation offers an attractive risk-reward, especially given PEG's business model, characterized by similar upside potential at lower risk. This is attributed to their repositioning and out-licensing strategy, enabling PEG to maintain a low-cost base and providing the potential to utilize their operational leverage when potential licensing agreements occur. All else being equal in our valuation model, the current valuation of PEG indicates a LoA equivalent to 7.0% or a royalty rate amounting to 7.3%, which illustrates, according to Analyst Group, that the full potential is not yet incorporated into the share price. Moreover, despite the difficulty in identifying perfect peers, an examination of comparable companies and their current pipelines indicates that there are grounds to believe PEG is presently trading at an unjustified discount. Lastly, recent transactions within PEG's indication areas and data on big pharma's willingness to make substantial upfront payments for phase II companies further support the thesis that PEG is currently flying under the radar for the investor collective.

FAVORABLE
RISK/REWARD

¹<https://www.jpmorgan.com/insights/outlook/market-outlook/biopharma-report-for-2023>


Bull scenario

In a Bull scenario, PEG is estimated to achieve a royalty rate of 25%, as well as strengthen its market position further, resulting in an increased market share and, consequently, a larger number of patients. Additionally, PEG could potentially be granted a Supplementary Protection Certificate (SPC) to extend the patent protection period for all candidates throughout the forecast period. Analyst Group estimates an additional five (5) years of extension to the patent protection, leading to increased total revenue through royalties for PEG. However, it's essential to note that the extended patent period is far in the future, resulting in the present value of these cash flows being relatively small compared to their nominal value. Assuming a LoA of 22% that PEG successfully manages to reach the commercialization phase and a WACC of 13.1%, a potential market value of DKK 2,366m is derived, corresponding to DKK 2.3 per share.¹

DKK 2.3
PER SHARE
(BULL SCENARIO)

Potential Market Value of DKK 2,366m, Equivalent to DKK 2.3 Per Share in a Bull scenario.

Risk-Adjusted NPV of FCF, Bull scenario 2025-2047E



Source: Analyst Group (estimates)


Bear scenario

In a Bear scenario, the estimated royalty rate is lower than the Base scenario, reaching 20%. Additionally, in a challenging market environment with heightened competition, PEG faces difficulties in achieving the targeted market shares and, consequently, is expected to attain substantially weaker market positions for all candidates. Applying a LoA of 22% and a WACC of 13.1%, a potential market value of DKK 543m is derived, equivalent to DKK 0.5 per share.¹

DKK 0.5
PER SHARE
(BEAR SCENARIO)

Potential Market Value of DKK 543m, Equivalent to DKK 0.5 Per Share in a Bear scenario.

Risk-Adjusted NPV of FCF, Bear scenario 2025-2042E



Source: Analyst Group (estimates)

¹See Appendix pages 23-24 for forecasts made in the Bull and Bear scenarios, respectively.



Thomas Kaas Selsø, Chief Executive Officer

Thomas Kaas Selsø (TKS) serves as CEO in Pharma Equity Group and in Reponex Pharmaceuticals and has more than 20 years of experience as CEO and CFO of various companies. He has extensive experience in financial management, financial accounting (IFRS & ÅRL), strategic analysis, M&A, valuation and due diligence. He has worked for different listed companies such as Lex Invest, Foreningen Fast Ejendom and DSV and for private equity funds such as Polaris and Maj-Invest. TKS has previously also been appointed by Kromann Reumert and Danske Bank as a board member in the reconstruction of the clothing company Moss Copenhagen and has previously been appointed by Jyske Bank in a financially distressed case. Additionally, Thomas has previously been CFO at North Risk A/S, a private equity fund owned group of companies. He has more than 17 years of experience as associate professor at the Copenhagen Business School (CBS), teaching in accountancy (IFRS & ÅRL) and M&A, among others, at different levels (MBA, CMA, HA, HD(R)).

Ownership: Thomas owns 1,822,474 shares in PEG.



Christopher Burton, Chief Medical Officer

Christopher Burton has been the CMO of Reponex Pharmaceutical A/S since June 1, 2023. Christopher is an accomplished and results-driven industry physician with extensive experience in clinical research and development. With a 25-year medical career, he graduated from Imperial College, London in 1998, worked as a registrar in clinical medicine, and holds a PhD in transplant immunology from the University of Copenhagen. Dr. Burton transitioned to the pharmaceutical industry in 2007 and has worked in both large and mid-sized companies like Novo Nordisk and ALK, as well as small MedTech and biotech firms. His expertise lies in developing strategies for pharmaceutical products across all development phases, and he has contributed to global initiatives in areas such as inflammation, immunology, metabolic disease, haematological and solid organ malignant disease. Dr. Burton has a broad network and contacts with key opinion leaders and professionals in the pharmaceutical industry.

Ownership: None



Lars Skriver, Chief Operating Officer

Lars Skriver is a highly experienced professional with a strong background in biochemistry, boasting over 40 years of expertise in lipid and protein chemistry. With over three decades of dedicated service in the pharmaceutical industry, he has held key leadership roles, including serving as the Co-founder and Managing Director at L&K Bioscience and as the COO at Serendex Pharmaceuticals A/S. Prior to that, Lars contributed his knowledge as a Senior Science Officer at Savara Pharmaceuticals and gained valuable experience through various pharmaceutical development positions at Novo Nordisk A/S. His wealth of experience encompasses extensive expertise in Chemistry, Manufacturing, and Controls (CMC), making him a valuable asset to the field.

Ownership: None



Lars Otto Uttenthal, Chief Scientific Officer

Lars Otto Uttenthal (Dr. Phil. Oxford) brings a wealth of expertise to the table with a distinguished career spanning over 45 years in clinical medicine and biomedical research. With a strong academic background, he has previously conducted research at renowned institutions such as the Universities of Oxford, London and Madrid, and held the position of Professor of Biochemistry at the University of Salamanca. In addition to his impressive research background, Dr. Uttenthal has over 22 years of experience in leading research and development efforts within the medical industry. Notably, he excels in the domain of intellectual property, having successfully conceived a considerable number of patent applications and navigated them through the application process, making him a valuable asset in the world of innovative healthcare.

Ownership: None



Christian Vinding Thomsen, Chairman of the Board

With over 20 years of experience, Christian specializes in Regulatory Life Science, Healthcare, M&A, and Corporate Law. He possesses extensive expertise in addressing legal matters pertinent to the pharmaceutical sector, having represented numerous companies in areas such as GCP, GMP, GDP, Market Access, and Marketing Compliance. Christian has served as a team leader in multiple large successful transactions including listings and mergers within the pharmaceutical industry. **Ownership:** Christian owns 1,233,605 shares in PEG.



Martin Engell-Rossen, Deputy Chairman of the Board

Martin Engell-Rossen is the owner of Engell-Rossen Strategy and is recognized as Denmark's leading political strategist. He is also currently an active board member in several companies and foundations. Mr. Engell-Rossen has an extensive career, including roles as Senior Vice President at Danfoss A/S, Chief of Staff at the Prime Minister's Office, and Special Advisor to Prime Minister Mette Frederiksen. He played a pivotal role in the Social Democrats' winning strategy in 2019 in the role as Chief of Staff, leading to their return to power. Mr. Engell-Rossen has held leading positions at large corporations such as Microsoft Denmark and TDC, and he possesses a Master of Corporate Communication from Copenhagen Business School (CBS), a Master of Political Science from Aarhus University, and a Master of International Relations from Jerusalem, Israel – affiliated with Gothenburg University in Sweden. **Ownership:** None



Peter Vilmann, Board Member

Peter Vilmann has advanced academic qualifications and expertise, as he holds a doctoral degree, a professorship, and is a licensed medical doctor at the Department of surgical Gastroenterology, Copenhagen University Herlev. **Ownership:** None



Lars Gundorph, Board Member

Lars Gundorph has worked with sales and risk management for many years and has successfully started several companies. In 2021, he was the mastermind behind the new advisory house, North Risk, which consists of the companies Contea (Risk management & insurance), Jysk Pension (Health and pension), Status (Mortgage advice) and FinPro (Financial Procurement). Since its inception, North has acquired additional companies and has approximately 170 employees. Lars has served on numerous boards since 2004. Currently, he serves as the chairman of the board for K/S City Hotels, a position he has held since 2008. Previously, Lars served on the boards of Willis Towers Watson, Sam Headhunting Group A/S, and Falck Healthcare A/S, among others. **Ownership:** Lars owns 21,351,475 shares in PEG.



Omar S. Qandeel - Board Member

Omar Qandeel has established partnerships with Japanese companies such as ShinMaywa Industries Ltd., FUJIFILM Corporation, Kawasaki, and Global Mobility Service Inc., serving as a consultant and advisor. His dedication to education has earned him positions in various educational institutions worldwide, including membership in the Perlmutter Institute Global Executive Council at Brandeis International Business School, vice-chairmanship at Universidad Camilo Jose Cela's international advisory board, and advisory roles at Fujita Health University and the Arrowsmith Program. With a vast international network, he expects to focus on securing funding from investors and to support the Company's commercial expansion into new markets, particularly in the Middle East and Asia. Currently, Mr. Qandeel holds management/advisory positions in Jose Camellia University and Fujita Medical University's advisory boards and serves as an advisor to the boards of Kawasaki and Shinmaywa Industries. **Ownership:** None

| Base scenario – Forecasted Royalties | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E |
|---|------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|------------|------------|
| RNX-011 | | | | | | | | | | | | | | | | | | |
| Prevalence (millions) | 1.1 | 1.2 | 1.2 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.7 | 1.7 | 1.7 |
| Market share | 0.7% | 1.4% | 3.5% | 5.6% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 7.0% | 2.3% | 1.4% | 0.7% |
| Treated patients (thousands) | 8 | 16 | 43 | 74 | 94 | 96 | 98 | 99 | 101 | 103 | 106 | 108 | 110 | 112 | 114 | 39 | 24 | 12 |
| Price per treatment (EURk) | 2.0 | | | | | | | | | | | | | | | | | |
| Total sales (EURm) | 15.4 | 32.7 | 86.6 | 147.0 | 187.5 | 191.2 | 195.0 | 198.9 | 202.9 | 207.0 | 211.1 | 215.3 | 219.6 | 224.0 | 228.5 | 77.7 | 47.5 | 24.2 |
| Royalties (EURm) | 23% | 3.5 | 7.3 | 19.5 | 33.1 | 42.2 | 43.0 | 43.9 | 44.8 | 45.7 | 46.6 | 47.5 | 48.4 | 49.4 | 50.4 | 17.5 | 10.7 | 5.5 |
| Risk-adjusted royalties (EURm) | 22% | 0.7 | 1.6 | 4.2 | 7.2 | 9.1 | 9.3 | 9.5 | 9.7 | 9.9 | 10.1 | 10.3 | 10.5 | 10.7 | 10.9 | 3.8 | 2.3 | 1.2 |
| RNX-021-23 | | | | | | | | | | | | | | | | | | |
| Prevalence (millions) | | 9.7 | 10.4 | 11.1 | 11.8 | 12.7 | 12.9 | 13.2 | 13.4 | 13.7 | 14.0 | 14.3 | 14.5 | | | | | |
| Market share | | 0.3% | 0.6% | 1.4% | 2.2% | 2.8% | 2.8% | 2.8% | 2.8% | 2.8% | 0.9% | 0.6% | 0.3% | | | | | |
| Treated patients (thousands) | | 27 | 58 | 155 | 265 | 354 | 361 | 369 | 376 | 384 | 130 | 80 | 41 | | | | | |
| Price per treatment (EURk) | 1.1 | | | | | | | | | | | | | | | | | |
| Total sales (EURm) | | 29.3 | 62.5 | 167.0 | 285.3 | 380.9 | 388.5 | 396.3 | 404.2 | 412.3 | 140.2 | 85.8 | 43.8 | | | | | |
| Royalties (EURm) | 23% | 6.6 | 14.1 | 37.6 | 64.2 | 85.7 | 87.4 | 89.2 | 90.9 | 92.8 | 31.5 | 19.3 | 9.8 | | | | | |
| Risk-adjusted royalties (EURm) | 22% | 1.4 | 3.0 | 8.1 | 13.9 | 18.6 | 18.9 | 19.3 | 19.7 | 20.1 | 6.8 | 4.2 | 2.1 | | | | | |
| RNX-041 | | | | | | | | | | | | | | | | | | |
| Crohn's | | | | | | | | | | | | | | | | | | |
| Prevalence (millions) | 1.8 | 1.9 | 1.9 | 2.0 | 2.0 | 2.1 | 2.2 | 2.2 | 2.3 | 2.3 | 2.4 | 2.4 | 2.4 | | | | | |
| Market share | 0.8% | 1.5% | 3.8% | 6.1% | 7.6% | 7.6% | 7.6% | 7.6% | 7.6% | 7.6% | 2.5% | 1.5% | 0.8% | | | | | |
| Treated patients (thousands) | 14 | 28 | 73 | 120 | 154 | 159 | 163 | 168 | 172 | 175 | 60 | 36 | 19 | | | | | |
| Price per treatment (EURk) | 3.5 | | | | | | | | | | | | | | | | | |
| Total sales (EURm) | 47.9 | 98.7 | 254.1 | 418.7 | 539.1 | 555.3 | 572.0 | 589.1 | 600.9 | 612.9 | 208.4 | 127.5 | 65.0 | | | | | |
| Royalties (EURm) | 23% | 10.8 | 22.2 | 57.2 | 94.2 | 121.3 | 124.9 | 128.7 | 132.6 | 135.2 | 137.9 | 46.9 | 28.7 | 14.6 | | | | |
| Risk-adjusted royalties (EURm) | 22% | 2.3 | 4.8 | 12.4 | 20.4 | 26.3 | 27.1 | 27.9 | 28.7 | 29.3 | 29.9 | 10.2 | 6.2 | 3.2 | | | | |
| Pouchitis | | | | | | | | | | | | | | | | | | |
| Prevalence (millions) | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | | | | | |
| Market share | 0.8% | 1.5% | 3.8% | 6.1% | 7.6% | 7.6% | 7.6% | 7.6% | 7.6% | 7.6% | 2.5% | 1.5% | 0.8% | | | | | |
| Treated patients (thousands) | 2 | 4 | 11 | 19 | 26 | 28 | 30 | 32 | 35 | 37 | 13 | 8 | 4 | | | | | |
| Price per treatment (EURk) | 3.5 | | | | | | | | | | | | | | | | | |
| Total sales (EURm) | 6.7 | 14.4 | 38.8 | 66.9 | 90.0 | 96.9 | 104.4 | 112.4 | 121.1 | 130.4 | 44.3 | 27.1 | 13.8 | | | | | |
| Royalties (EURm) | 1.5 | 3.2 | 8.7 | 15.0 | 20.3 | 21.8 | 23.5 | 25.3 | 27.2 | 29.3 | 10.0 | 6.1 | 3.1 | | | | | |
| Risk-adjusted royalties (EURm) | 22% | 0.3 | 0.7 | 1.9 | 3.3 | 4.4 | 4.7 | 5.1 | 5.5 | 5.9 | 6.4 | 2.2 | 1.3 | 0.7 | | | | |
| RNX-051 | | | | | | | | | | | | | | | | | | |
| Prevalence (millions) | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | | | | | |
| Market share | 1.5% | 3.0% | 7.5% | 12.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | 15.0% | | | | | |
| Treated patients (thousands) | 10 | 22 | 56 | 93 | 121 | 126 | 129 | 131 | 134 | 136 | 139 | 142 | 145 | | | | | |
| Price per treatment (EURk) | 3.0 | | | | | | | | | | | | | | | | | |
| Total sales (EURm) | 31.1 | 64.6 | 168.0 | 279.6 | 363.4 | 378.0 | 385.5 | 393.2 | 401.1 | 409.1 | 417.3 | 425.7 | 434.2 | | | | | |
| Royalties (EURm) | 23% | 7.0 | 14.5 | 37.8 | 62.9 | 81.8 | 85.0 | 86.7 | 88.5 | 90.2 | 92.1 | 93.9 | 95.8 | 97.7 | | | | |
| Risk-adjusted royalties (EURm) | 22% | 1.5 | 3.1 | 8.2 | 13.6 | 17.7 | 18.4 | 18.8 | 19.2 | 19.5 | 19.9 | 20.3 | 20.7 | 21.2 | | | | |
| Total Risk-adjusted royalties (EURm) | 4.9 | 11.7 | 29.7 | 52.6 | 71.4 | 78.1 | 80.2 | 82.4 | 84.3 | 86.3 | 49.8 | 43.0 | 37.8 | 32.5 | 18.5 | 8.3 | 4.6 | 1.2 |

| Base scenario Income statement (DKKm) | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E |
|--|-------------|-------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|-------------|-------------|--------------|
| Risk-adj. royalties (EURm) | 4.9 | 11.7 | 29.7 | 52.6 | 71.4 | 78.1 | 80.2 | 82.4 | 84.3 | 86.3 | 49.8 | 43.0 | 37.8 | 32.5 | 18.5 | 8.3 | 4.6 | 1.2 |
| EUR/DKK (7.45) | | | | | | | | | | | | | | | | | | |
| Risk-adj. royalties (DKKm) | 36.7 | 87.0 | 221.5 | 391.8 | 532.0 | 581.8 | 597.4 | 613.6 | 628.2 | 643.3 | 370.8 | 320.0 | 281.9 | 242.1 | 137.6 | 61.7 | 34.3 | 8.8 |
| COGS | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Gross profit | 34.7 | 85.0 | 219.5 | 389.8 | 530.0 | 579.8 | 595.4 | 611.6 | 626.2 | 641.3 | 368.8 | 318.0 | 279.9 | 240.1 | 135.6 | 59.7 | 32.3 | 6.8 |
| R&D | -15.0 | -20.0 | -17.5 | -15.0 | -12.5 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 |
| Administrative costs | -12.0 | -13.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 |
| EBIT | 7.7 | 52.0 | 188.0 | 360.8 | 503.5 | 555.8 | 571.4 | 587.6 | 602.2 | 617.3 | 344.8 | 294.0 | 255.9 | 216.1 | 111.6 | 35.7 | 8.3 | -17.2 |
| Interest | -3.0 | -2.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT | 4.7 | 50.0 | 187.0 | 360.8 | 503.5 | 555.8 | 571.4 | 587.6 | 602.2 | 617.3 | 344.8 | 294.0 | 255.9 | 216.1 | 111.6 | 35.7 | 8.3 | -17.2 |
| Tax | -1.0 | -11.0 | -41.1 | -79.4 | -110.8 | -122.3 | -125.7 | -129.3 | -132.5 | -135.8 | -75.9 | -64.7 | -56.3 | -47.5 | -24.6 | -7.8 | -1.8 | 0.0 |
| Net income | 3.7 | 39.0 | 145.9 | 281.4 | 392.8 | 433.5 | 445.7 | 458.3 | 469.7 | 481.5 | 269.0 | 229.4 | 199.6 | 168.6 | 87.1 | 27.8 | 6.5 | -17.2 |
| Base scenario - rNPV-model (DKKm) | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E |
| NOPAT | 6.0 | 40.6 | 146.6 | 281.4 | 392.8 | 433.5 | 445.7 | 458.3 | 469.7 | 481.5 | 269.0 | 229.4 | 199.6 | 168.6 | 87.1 | 27.8 | 6.5 | -13.4 |
| + Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Capex | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Increase in NWC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Risk-Adjusted FCF | 6.0 | 40.6 | 146.6 | 281.4 | 392.8 | 433.5 | 445.7 | 458.3 | 469.7 | 481.5 | 269.0 | 229.4 | 199.6 | 168.6 | 87.1 | 27.8 | 6.5 | -13.4 |
| WACC (13.1%) | | | | | | | | | | | | | | | | | | |
| Discounting period | 1.8 | 2.8 | 3.8 | 4.8 | 5.8 | 6.8 | 7.8 | 8.8 | 9.8 | 10.8 | 11.8 | 12.8 | 13.8 | 14.8 | 15.8 | 16.8 | 16.8 | 17.9 |
| Discount factor | 0.797 | 0.705 | 0.624 | 0.552 | 0.488 | 0.432 | 0.382 | 0.338 | 0.299 | 0.265 | 0.234 | 0.207 | 0.183 | 0.162 | 0.143 | 0.127 | 0.127 | 0.112 |
| Net Present Value (rNPV) | 4.8 | 28.6 | 91.5 | 155.4 | 191.8 | 187.3 | 170.3 | 155.0 | 140.5 | 127.4 | 63.0 | 47.5 | 36.6 | 27.3 | 12.5 | 3.5 | 0.8 | -1.5 |

¹EUR/DKK as of 2024-02-26

| Bull scenario Income statement (DKKm) | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E | 2043E | 2044E | 2045E | 2046E | 2047E |
|--|-------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|-------------|-------------|--------------|
| Risk-adj. royalties (EURm) | 6.6 | 15.6 | 39.6 | 70.1 | 95.2 | 104.1 | 106.9 | 109.8 | 112.4 | 115.1 | 111.7 | 112.7 | 114.1 | 116.4 | 99.1 | 47.1 | 34.8 | 27.7 | 19.2 | 27.2 | 12.2 | 6.8 | 1.7 |
| EUR/DKK (7.45) | | | | | | | | | | | | | | | | | | | | | | | |
| Risk-adj. royalties (DKKm) | 48.9 | 116.0 | 295.3 | 522.4 | 709.4 | 775.7 | 796.6 | 818.2 | 837.6 | 857.7 | 831.9 | 839.8 | 849.9 | 866.9 | 738.5 | 350.9 | 259.1 | 206.1 | 143.4 | 202.6 | 90.8 | 50.5 | 13.0 |
| COGS | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Gross profit | 46.9 | 114.0 | 293.3 | 520.4 | 707.4 | 773.7 | 794.6 | 816.2 | 835.6 | 855.7 | 829.9 | 837.8 | 847.9 | 864.9 | 736.5 | 348.9 | 257.1 | 204.1 | 141.4 | 200.6 | 88.8 | 48.5 | 11.0 |
| R&D | -15.0 | -20.0 | -17.5 | -15.0 | -12.5 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 |
| Administrative costs | -12.0 | -13.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 | -14.0 |
| EBIT | 19.9 | 81.0 | 261.8 | 491.4 | 680.9 | 749.7 | 770.6 | 792.2 | 811.6 | 831.7 | 805.9 | 813.8 | 823.9 | 840.9 | 712.5 | 324.9 | 233.1 | 180.1 | 117.4 | 176.6 | 64.8 | 24.5 | -13.0 |
| Interest | -3.0 | -2.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT | 16.9 | 79.0 | 260.8 | 491.4 | 680.9 | 749.7 | 770.6 | 792.2 | 811.6 | 831.7 | 805.9 | 813.8 | 823.9 | 840.9 | 712.5 | 324.9 | 233.1 | 180.1 | 117.4 | 176.6 | 64.8 | 24.5 | -13.0 |
| Tax | -3.7 | -17.4 | -57.4 | #### | -149.8 | -164.9 | -169.5 | -174.3 | -178.6 | -183.0 | -177.3 | -179.0 | -181.3 | -185.0 | -156.7 | -71.5 | -51.3 | -39.6 | -25.8 | -38.9 | -14.3 | -5.4 | 0.0 |
| Net income | 13.2 | 61.6 | 203.4 | 383.3 | 531.1 | 584.8 | 601.0 | 617.9 | 633.1 | 648.7 | 628.6 | 634.8 | 642.7 | 655.9 | 555.7 | 253.4 | 181.8 | 140.5 | 91.6 | 137.8 | 50.5 | 19.1 | -13.0 |
| Bull scenario rNPV-model (DKKm) | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E | 2043E | 2044E | 2045E | 2046E | 2047E |
| NOPAT | 15.5 | 63.2 | 204.2 | 383.3 | 531.1 | 584.8 | 601.0 | 617.9 | 633.1 | 648.7 | 628.6 | 634.8 | 642.7 | 655.9 | 555.7 | 253.4 | 181.8 | 140.5 | 91.6 | 137.8 | 50.5 | 19.1 | -10.2 |
| + Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Capex | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Increase in NWC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Risk-Adjusted FCF | 15.5 | 63.2 | 204.2 | 383.3 | 531.1 | 584.8 | 601.0 | 617.9 | 633.1 | 648.7 | 628.6 | 634.8 | 642.7 | 655.9 | 555.7 | 253.4 | 181.8 | 140.5 | 91.6 | 137.8 | 50.5 | 19.1 | -10.2 |
| WACC (13.1%) | | | | | | | | | | | | | | | | | | | | | | | |
| Discounting period | 1.8 | 2.8 | 3.8 | 4.8 | 5.8 | 6.8 | 7.8 | 8.8 | 9.8 | 10.8 | 11.8 | 12.8 | 13.8 | 14.8 | 15.8 | 16.8 | 16.8 | 17.9 | 18.9 | 19.9 | 20.9 | 21.9 | 22.9 |
| Discount factor | 0.797 | 0.705 | 0.624 | 0.552 | 0.488 | 0.432 | 0.382 | 0.338 | 0.299 | 0.265 | 0.234 | 0.207 | 0.183 | 0.162 | 0.143 | 0.127 | 0.127 | 0.112 | 0.099 | 0.088 | 0.078 | 0.069 | 0.061 |
| Net Present Value (rNPV) | 12.4 | 44.6 | 127.4 | 211.6 | 259.4 | 252.6 | 229.7 | 208.9 | 189.3 | 171.6 | 147.1 | 131.4 | 117.7 | 106.3 | 79.7 | 32.1 | 23.1 | 15.8 | 9.1 | 12.1 | 3.9 | 1.3 | -0.6 |

¹EUR/DKK as of 2024-02-26

| Bear scenario | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E |
|--|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Income statement (DKKm) | | | | | | | | | | | | | | | | | | |
| Risk-adj. royalties (EURm) | 2.2 | 5.2 | 13.2 | 23.4 | 31.7 | 34.7 | 35.6 | 36.6 | 37.5 | 38.4 | 22.1 | 19.1 | 16.8 | 14.4 | 8.2 | 3.7 | 2.0 | 0.5 |
| EUR/DKK (7.45) | | | | | | | | | | | | | | | | | | |
| Risk-adj. royalties (DKKm) | 16.3 | 38.7 | 98.4 | 174.1 | 236.5 | 258.6 | 265.5 | 272.7 | 279.2 | 285.9 | 164.8 | 142.2 | 125.3 | 107.6 | 61.2 | 27.4 | 15.3 | 3.9 |
| COGS | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 | -2.0 |
| Gross profit | 14.3 | 36.7 | 96.4 | 172.1 | 234.5 | 256.6 | 263.5 | 270.7 | 277.2 | 283.9 | 162.8 | 140.2 | 123.3 | 105.6 | 59.2 | 25.4 | 13.3 | 1.9 |
| R&D | -15.0 | -20.0 | -17.5 | -15.0 | -12.5 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 | -10.0 |
| Administrative costs | | | | | | | | | | | | | | | | | | |
| EBIT | -0.7 | 16.7 | 78.9 | 157.1 | 222.0 | 246.6 | 253.5 | 260.7 | 267.2 | 273.9 | 152.8 | 130.2 | 113.3 | 95.6 | 49.2 | 15.4 | 3.3 | -8.1 |
| Interest | -3.0 | -2.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBT | -3.7 | 14.7 | 77.9 | 157.1 | 222.0 | 246.6 | 253.5 | 260.7 | 267.2 | 273.9 | 152.8 | 130.2 | 113.3 | 95.6 | 49.2 | 15.4 | 3.3 | -8.1 |
| Tax | 0.0 | -0.4 | -14.1 | -31.5 | -45.8 | -51.2 | -52.7 | -54.3 | -55.7 | -57.2 | -30.5 | -25.6 | -21.8 | -18.0 | -7.7 | -0.3 | 0.0 | 0.0 |
| Net income | -3.7 | 14.3 | 63.9 | 125.7 | 176.2 | 195.4 | 200.8 | 206.4 | 211.5 | 216.7 | 122.3 | 104.7 | 91.4 | 77.7 | 41.4 | 15.1 | 3.3 | -8.1 |
| Bear scenario - rNPV-model (DKKm) | 2025E | 2026E | 2027E | 2028E | 2029E | 2030E | 2031E | 2032E | 2033E | 2034E | 2035E | 2036E | 2037E | 2038E | 2039E | 2040E | 2041E | 2042E |
| NOPAT | -9.9 | 2.9 | 50.7 | 111.7 | 162.2 | 181.4 | 186.8 | 192.4 | 197.5 | 202.7 | 108.3 | 90.7 | 77.4 | 63.7 | 27.4 | 1.1 | -8.4 | -17.2 |
| + Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Capex | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| - Increase in NWC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Risk-Adjusted FCF | -9.9 | 2.9 | 50.7 | 111.7 | 162.2 | 181.4 | 186.8 | 192.4 | 197.5 | 202.7 | 108.3 | 90.7 | 77.4 | 63.7 | 27.4 | 1.1 | -8.4 | -17.2 |
| WACC (13.1%) | | | | | | | | | | | | | | | | | | |
| Discounting period | 1.8 | 2.8 | 3.8 | 4.8 | 5.8 | 6.8 | 7.8 | 8.8 | 9.8 | 10.8 | 11.8 | 12.8 | 13.8 | 14.8 | 15.8 | 16.8 | 16.8 | 17.9 |
| Discount factor | 0.797 | 0.705 | 0.624 | 0.552 | 0.488 | 0.432 | 0.382 | 0.338 | 0.299 | 0.265 | 0.234 | 0.207 | 0.183 | 0.162 | 0.143 | 0.127 | 0.127 | 0.112 |
| Net Present Value (rNPV) | -7.9 | 2.0 | 31.6 | 61.6 | 79.2 | 78.4 | 71.4 | 65.1 | 59.1 | 53.6 | 25.3 | 18.8 | 14.2 | 10.3 | 3.9 | 0.1 | -1.1 | -1.9 |

¹EUR/DKK as of 2024-02-26

| Application/publication no. | Drug candidate | Priority date | Patent expiration ¹ | Patent life (years) ¹ | Title | Status |
|--|------------------|---------------|--------------------------------|----------------------------------|--|--|
| WO2016020530A1 (priority DK PA2014 70473) | RNX-011 | 07.08.2014 | 2035 | 11 | "Compositions for treatment of peritonitis" | Granted in EU, US and Japan |
| Priority DK PA2019 70266 | RNX-011 | 28.04.2019 | 2040 | 16 | "Composition for the intraperitoneal treatment of secondary bacterial peritonitis with reduction of complications" | National phase in US |
| WO2015177379A3 (priority DK PA2014 70300) | RNX-021, RNX-022 | 23.05.2014 | 2035 | 11 | "Compositions for promoting the healing of wounds" | National phase in EU, US and Japan |
| WO2015118069A1 (priority DK PA2014 70059) | RNX-023 | 05.04.2014 | 2035 | 11 | "Compositions for promoting the healing of skin ulcers and wounds" | Granted in EU and Russia National phase in US and Japan |
| WO2016012608A1 (priority DK PA2014 70461) | RNX-041 | 25.07.2014 | 2035 | 11 | "GM-CSF for treatment of IBD" | Granted in US National phase in EU |
| PCT/EP2019/050798 (priority DK PA2018 70030) (priority DK PA2018 70392) | RNX-051 | 17.01.2018 | 2039 | 15 | "Compositions for eliminating bacterial promoters of colorectal cancer by intraluminal application" | National phase in EU, US, Japan, Russia |

| Candidate | Indication | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 |
|------------|-------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| RNX-011 | Peritonitis | | | | | | | | | | | | | | | | | | |
| RNX-021-23 | Chronic Wounds | | | | | | | | | | | | | | | | | | |
| RNX-041 | Crohn's | | | | | | | | | | | | | | | | | | |
| | Pouchitis | | | | | | | | | | | | | | | | | | |
| RNX-051 | Colorectal cancer | | | | | | | | | | | | | | | | | | |

Expected Income

Ramp Up

Maturity

Patent Expiration

¹The patent expiration does not account for the potential Supplementary Protection Certificate (SPC), which could extend the patent duration by an additional 5 years in the EU.

Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, Pharma Equity Group A/S (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2024). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.